Overview: The trial is designed to evaluate the safety of CNP-103 and explore if it may help protect insulin-producing beta cells that support better blood sugar control. Participants will be 12 - 35 years old, male or female, and diagnosed with Stage 3 T1D within the last 6 months.
Overview: This study evaluates the safety and effectiveness of a medication aiming to preserve function of insulin producing cells. Participants will be ages 1 to 25, male or female.
Overview: You could be part of a clinical study programme that helps get more information on how a new, once-weekly insulin product, helps in reducing the blood sugar compared with insulin products taken once daily.
Overview: This study is testing an investigational study drug in people recently diagnosed with type 1 diabetes.
Fill out the form below an we will let you know when a study becomes available that you may be interested in:
